ING Groep NV Sells 5,041 Shares of Hologic, Inc. (NASDAQ:HOLX)

Key Points

• ING Groep NV reduced its stake in Hologic, Inc. by 55.4%, selling 5,041 shares and holding 4,052 shares valued at $250,000, according to its latest SEC filing.
• Hologic's stock traded at $68.06 with a market cap of $15.14 billion, and the company reported a 1.2% year-over-year revenue increase of $1.02 billion for the last quarter.
• A total of 94.73% of Hologic's stock is owned by institutional investors, with several raising their positions significantly during the 4th quarter of the previous year.

ING Groep NV lowered its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 55.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,052 shares of the medical equipment provider's stock after selling 5,041 shares during the quarter. ING Groep NV's holdings in Hologic were worth $250,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of HOLX. Resona Asset Management Co. Ltd. purchased a new position in Hologic in the 4th quarter worth about $6,090,000. Federated Hermes Inc. boosted its position in Hologic by 35.8% during the 4th quarter. Federated Hermes Inc. now owns 7,720 shares of the medical equipment provider's stock worth $557,000 after acquiring an additional 2,036 shares during the period. Bank of Montreal Can boosted its position in Hologic by 45.1% during the 4th quarter. Bank of Montreal Can now owns 714,377 shares of the medical equipment provider's stock worth $51,499,000 after acquiring an additional 222,167 shares during the period. Invesco Ltd. boosted its position in Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after acquiring an additional 572,187 shares during the period. Finally, Bank of Nova Scotia boosted its position in Hologic by 227.8% during the 4th quarter. Bank of Nova Scotia now owns 97,612 shares of the medical equipment provider's stock worth $7,037,000 after acquiring an additional 67,832 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

HOLX traded up $0.13 on Friday, hitting $68.06. The company had a trading volume of 1,889,601 shares, compared to its average volume of 1,757,182. The company's fifty day moving average price is $65.09 and its 200 day moving average price is $62.74. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock has a market cap of $15.14 billion, a price-to-earnings ratio of 28.24, a price-to-earnings-growth ratio of 2.46 and a beta of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the company earned $1.06 EPS. The company's revenue for the quarter was up 1.2% on a year-over-year basis. Equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Morgan Stanley raised their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Evercore ISI raised their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. UBS Group raised their price objective on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, July 31st. Finally, Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and lifted their price target for the company from $72.00 to $87.00 in a report on Wednesday. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $77.83.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.